Ritter Pharmaceuticals (NASDAQ:RTTR) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday, ValuEngine reports.
Separately, Zacks Investment Research cut shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 17th.
Shares of NASDAQ RTTR traded up $0.07 during midday trading on Monday, hitting $0.31. 2,414,999 shares of the company traded hands, compared to its average volume of 477,448. Ritter Pharmaceuticals has a 12-month low of $0.23 and a 12-month high of $2.56. The stock has a 50-day moving average price of $0.76 and a 200 day moving average price of $0.89. The firm has a market cap of $2.27 million, a P/E ratio of -0.08 and a beta of 1.24.
Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.18.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.
Further Reading: Market Timing – The Benefits and the Danger
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.